Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma

Yazar
Dagoglu, Nergiz
Karabulut, Senem
Gonenc, Murat
Tas, Faruk
Serilmez, Murat
Afsar, Cıgdem Usul
Karabulut, Mehmet
Alis, Halil
Üst veri
Tüm öğe kaydını göster
Özet
Background: This study was conducted to investigate the serum levels of interleukin-18 (IL-18) in patients with pancreatic adenocarcinoma (PA) and the relationship with tumor progression and known prognostic parameters.
Bağlantı
http://hdl.handle.net/20.500.12627/39941
https://doi.org/10.1016/j.jiac.2016.12.003
Koleksiyonlar